This study suggests that the presence of AIDS and COVID-19 are factors associated with the risk of D-VL, while the duration of HAART and prescriber’s perception of adherence to therapy and Nadir CD4+ T-cell levels are associated with a lower risk of D-VL. The gene discussed is CD4; the disease is COVID-19.